Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 306 results found since Jan 2013.
Serologic Biomarkers in Pemphigus Monitoring: C-reactive Protein, Macrophage Migration Inhibitory Factor, and Prolactin Levels Versus Autoantibody Assays
In conclusion, anti-Dsg1, anti-Dsg3, and IIF autoantibody titers remain standard biomarkers for assessing disease activity, severity, and PV monitoring. The trend of CRP was similar to that of anti-Dsg1, anti-Dsg3, and IIF. Thus, CRP may be used for PV monitoring.PMID:37524667 | DOI:10.18502/ijaai.v22i3.13059
Source: Iranian Journal of Allergy, Asthma and Immunology - July 31, 2023 Category: Allergy & Immunology Authors: Hossein Mortazavi Vahide Saeidi Kamran Balighi Nafiseh Esmaeili Amir Teimourpour Maryam Daneshpazhooh Shahin Hamzelou Zahra Saffarian Jafar Taghizadeh Fazli Source Type: research
Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab
Ann Allergy Asthma Immunol. 2023 Jan 24:S1081-1206(23)00042-X. doi: 10.1016/j.anai.2023.01.018. Online ahead of print.ABSTRACTRituximab is a chimeric anti-CD20 monoclonal antibody that targets CD20-expressing B-lymphocytes, has a well-defined efficacy and safety profile, and is broadly used to treat a wide array of diseases. In this review, we cover the mechanism of action of rituximab and focus on hypogammaglobulinemia and late-onset neutropenia-two immune effects secondary to rituximab-as well as subsequent infection. We review risk factors and highlight key considerations for immunological monitoring and clinical manage...
Source: Annals of Allergy, Asthma and Immunology - January 27, 2023 Category: Allergy & Immunology Authors: Tejas S Athni Sara Barmettler Source Type: research
Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes
CONCLUSION: Immunotherapeutic can be a better option for preventing and protecting type one diabetes. Since, the existing literature does not have enough data to support any single drug concluding the same will not be appropriate. Hence further studies are required wherein different drugs can be compared with similar sample sizes for each group of drugs.PMID:36415095 | DOI:10.2174/2772270817666221122103029
Source: Adv Data - November 23, 2022 Category: Epidemiology Authors: Prajakta Kashalikar Shivani Desai Avinash Sanap Madhura Shekatkar Ramesh Bhonde Source Type: research
